Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

INTERLACE

- PMLiVE

Cancer Research UK partners with French cancer institute

Both organisations will support the global Cancer Grand Challenges initiative

- PMLiVE

COVID-19 could be key in identifying viruses with pandemic potential

Researchers analysed major variants of concern, including the Omicron subvariants

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study

More than two million people worldwide are diagnosed with breast cancer every year

- PMLiVE

ICR and Merck renew strategic alliance for development of new cancer drugs

The latest agreement builds on 20 years of collaboration between the two partners

- PMLiVE

Merck announces partnerships worth $1.3bn with BenevolentAI and Exscientia

The deals aim to accelerate drug development in oncology, neurology and immunology

EU flag

EC approves Menarini Group’s Orserdu for advanced or metastatic breast cancer

More than 550,000 people are diagnosed with breast cancer each year in Europe

- PMLiVE

MIT study reveals why certain immunotherapies do not always work

The findings could help doctors determine which drugs would benefit patients most

- PMLiVE

Researchers discover how neurons die in Alzheimer’s disease

The findings open up potential avenues to develop new treatments for the condition

- PMLiVE

ICR researchers develop new test to help identify future cancer treatments

The RKD2 test could make the early stages of drug discovery for cancer more efficient

- PMLiVE

Date set for EU antitrust regulators to decide on Pfizer’s $43bn Seagen acquisition

The proposed transaction would mark a significant boost to the US pharma’s oncology pipeline

- PMLiVE

FDA boosts collaboration with manufacturers to overcome ongoing cancer drug shortages

The supply of cisplatin, carboplatin and methotrexate has nearly halved in the past year

- PMLiVE

BMS presents positive six-year results for Opdivo/Yervoy combination in lung cancer

NSCLC is the most common type of lung cancer, representing up to 85% of diagnoses

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links